1 |
Etoposide
| 1件: Etoposide Etoposide | 1件: Etoposide Etoposide; | 2件: TOP2A TOP2A, TOP2B 💬 | 1件: Platinum drug resistance Platinum drug resistance 💬 | 11件: 11 11, 13, 14, 26, 28, 34, 60, 65, 85, 164, 331 |
2 |
Cyclosporine
| 1件: Cyclosporine Cyclosporine | 10件: Ciclosporin Ciclosporin; Ciclosporina; Ciclosporine; Cyclosporin; Cyclosporin A; Cyclosporine; Cyclosporine A; Ikervis; NEORAL; RESTASIS; | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 44件: 11 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
3 |
Cyclophosphamide
| 1件: Cyclophosphamide Cyclophosphamide | 6件: Ciclofosfamida Ciclofosfamida; Ciclofosfamide; Cyclophosphamid; Cyclophosphamide; Cyclophosphamidum; Cytoxan; | - | - | 44件: 11 11, 13, 14, 16, 19, 20, 26, 28, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 56, 60, 62, 65, 66, 84, 85, 93, 96, 162, 164, 172, 205, 222, 224, 256, 274, 283, 284, 285, 288, 326, 331 |
4 |
Lamivudine
| 1件: Lamivudine Lamivudine | 4件: COMBIVIR COMBIVIR; Epivir; Lamivudine; Triumeq; | - | - | 8件: 2 2, 26, 42, 46, 135, 256, 265, 325 |
5 |
Valproic acid
| 1件: Valproic acid Valproic acid | 3件: Valproate Valproate; VALPROATE SODIUM; Valproic Acid; | 7件: ABAT ABAT, ALDH5A1, CACNA1G, CACNA1H, CACNA1I, GAD1, GAD2 💬 | 17件: Alanine, aspartate and glutamate metabolism Alanine, aspartate and glutamate metabolism, Aldosterone synthesis and secretion, Butanoate metabolism, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, GABAergic synapse, GnRH secretion, MAPK signaling pathway, Metabolic pathways, Propanoate metabolism, Taurine and hypotaurine metabolism, Type I diabetes mellitus, Type II diabetes mellitus, Valine, leucine and isoleucine degradation, beta-Alanine metabolism 💬 | 14件: 2 2, 3, 5, 6, 13, 26, 65, 85, 90, 102, 127, 222, 233, 256 |
6 |
Methylprednisolone
| 1件: Methylprednisolone Methylprednisolone | 4件: Medrol Medrol; Methylprednisolon; Methylprednisolone; Methylprednisolone acetate; | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 46件: 2 2, 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 85, 86, 93, 95, 96, 97, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296 |
7 |
Zidovudine
| 1件: Zidovudine Zidovudine | 3件: COMBIVIR COMBIVIR; Retrovir; Zidovudine; | - | - | 7件: 25 25, 26, 94, 135, 265, 325, 331 |
8 |
Prednisolone
| 1件: Prednisolone Prednisolone | 3件: Prednisolona Prednisolona; PREDNISOLONE; Prednisolonum; | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 42件: 3 3, 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300 |
9 |
Prednisone
| 1件: Prednisone Prednisone | 3件: Prednisona Prednisona; Prednisone; RAYOS; | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 45件: 2 2, 11, 13, 14, 19, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 79, 81, 84, 85, 86, 95, 96, 97, 113, 162, 164, 205, 222, 224, 228, 283, 284, 288, 299, 300, 307, 331 |
10 |
Pentoxifylline
| 1件: Pentoxifylline Pentoxifylline | 1件: Pentoxifylline Pentoxifylline; | - | - | 12件: 26 26, 56, 84, 86, 93, 96, 97, 113, 220, 222, 296, 298 |
11 |
Tamibarotene
| 1件: Tamibarotene Tamibarotene | 1件: Tamibarotene Tamibarotene; | 1件: RARA RARA 💬 | 5件: Acute myeloid leukemia Acute myeloid leukemia, Estrogen signaling pathway, Pathways in cancer, Th17 cell differentiation, Transcriptional misregulation in cancer 💬 | 2件: 26 26, 96 |
12 |
Rituximab
| 1件: Rituximab Rituximab | 6件: MabThera MabThera; Rituxan; Rituximab; Rixathon; Ruxience; TRUXIMA; | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 48件: 11 11, 13, 14, 19, 26, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331 |
13 |
Bortezomib
| 1件: Bortezomib Bortezomib | 3件: Bortezomib Bortezomib; Bortezomib Accord; Velcade; | 1件: PSMB5 PSMB5 💬 | 8件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬 | 17件: 11 11, 13, 26, 28, 46, 49, 51, 61, 63, 64, 66, 222, 228, 256, 283, 288, 331 |
14 |
Filgrastim
| 1件: Filgrastim Filgrastim | 7件: Filgrastim Filgrastim; Filgrastim Hexal; G-CSF; Granulocyte Colony Stimulating Factor; NEUPOGEN; TEVAGRASTIM; ZARZIO; | 1件: CSF3R CSF3R 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬 | 35件: 2 2, 6, 11, 13, 16, 22, 25, 26, 28, 34, 35, 36, 38, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331 |
15 |
Interferon alfa
| 1件: Interferon alfa Interferon alfa | 1件: Interferon alfa Interferon alfa; | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 6件: 13 13, 25, 26, 28, 56, 96 |
16 |
Doxorubicin
| 1件: Doxorubicin Doxorubicin | 2件: Doxorubicin Doxorubicin; Doxorubicin Hydrochloride; | 2件: TOP2A TOP2A, TOP2B 💬 | 1件: Platinum drug resistance Platinum drug resistance 💬 | 5件: 26 26, 28, 34, 65, 331 |
17 |
Interferon beta-1a
| 1件: Interferon beta-1a Interferon beta-1a | 6件: AVONEX AVONEX; Interferon Beta 1-A; Interferon Beta 1a; Interferon beta-1a; Interferon-beta-1a; REBIF; | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 4件: 13 13, 26, 96, 97 |
18 |
Lenalidomide
| 1件: Lenalidomide Lenalidomide | 2件: Lenalidomide Lenalidomide; REVLIMID; | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 8件: 16 16, 26, 28, 34, 49, 284, 300, 331 |
19 |
Raltegravir
| 1件: Raltegravir Raltegravir | 2件: ISENTRESS ISENTRESS; Raltegravir; | - | - | 4件: 13 13, 26, 93, 265 |
20 |
Cyclophosphamide
| 1件: Cyclophosphamide Cyclophosphamide | 6件: Ciclofosfamida Ciclofosfamida; Ciclofosfamide; Cyclophosphamid; Cyclophosphamide; Cyclophosphamidum; Cytoxan; | - | - | 44件: 11 11, 13, 14, 16, 19, 20, 26, 28, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 56, 60, 62, 65, 66, 84, 85, 93, 96, 162, 164, 172, 205, 222, 224, 256, 274, 283, 284, 285, 288, 326, 331 |
21 |
Vincristine
| 1件: Vincristine Vincristine | 2件: Vincristine Vincristine; Vincristine Sulfate; | 9件: TUBB TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 10件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Gap junction, Huntington disease, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 4件: 26 26, 34, 65, 331 |
22 |
Mogamulizumab
| 1件: Mogamulizumab Mogamulizumab | 1件: Mogamulizumab Mogamulizumab; | 1件: CCR4 CCR4 💬 | 5件: Chemokine signaling pathway Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Kaposi sarcoma-associated herpesvirus infection, Viral carcinogenesis, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 26 26 |
23 |
Teriflunomide
| 1件: Teriflunomide Teriflunomide | 2件: AUBAGIO AUBAGIO; Teriflunomide; | 1件: DHODH DHODH 💬 | 3件: Biosynthesis of cofactors Biosynthesis of cofactors, Metabolic pathways, Pyrimidine metabolism 💬 | 3件: 13 13, 25, 26 |
24 |
Nivolumab
| 1件: Nivolumab Nivolumab | 1件: Nivolumab Nivolumab; | 1件: PDCD1 PDCD1 💬 | 3件: Cell adhesion molecules Cell adhesion molecules, PD-L1 expression and PD-1 checkpoint pathway in cancer, T cell receptor signaling pathway 💬 | 12件: 13 13, 26, 41, 46, 49, 50, 51, 53, 85, 96, 97, 159 |